&w=3840&q=100)
Escorts Kubota eyes No 2 spot in Indian tractor market with new launches
Farm machinery and construction equipment major Escorts Kubota Ltd is gunning for the number two spot in the Indian tractor market by combining the Indian firm's cost competitiveness with the Japanese partner's technology and quality strengths as part of its future plans, according to its top officials.
The company, formed after Japan's Kubota Corporation acquired a majority stake in Escorts Ltd in a multi-structured merger deal announced in 2021, is working to finalise a mid-term plan (MTP) for up to 2031 with a slew of products planned to be launched, Escorts Kubota Ltd (EKL) Chairman and MD Nikhil Nanda and Deputy MD Seiji Fukuoka told PTI in a joint interview.
"In the next four to five years between the three brands -- Farmtrac, Powertrac and Kubota -- I think the success is going to come from the new products that we are going to be launching. Lot of work has happened, and a lot of product lines are planned for introduction between now and the next five years...," Nanda said responding to a query on the road ahead.
These products are for domestic as well as international markets and for different applications, and also for the construction business as well, he added without elaborating details.
"Product planning, innovation and development is going to play an extremely important role for the kind of growth that we are envisioning," Nanda said.
When asked about the company's growth ambitions, Fukuoka said,"In the domestic market, our first target would be to get to number two position. Presently, our market share is somewhere between 12 to 13 per cent." EKL is a distant fourth in the Indian tractor market that is currently led by Mahindra-Swaraj combined with around 40 per cent share. TAFE and Sonalika are the other players in the top three, he noted.
In FY25, tractor retail sales were at 8,83,095 units as against 8,92,410 units in FY24, according to Federation of Automobile Dealers Associations (FADA) data.
Both Nanda and Fukuoka declined to put a timeline to their target to become the number two player in the Indian market reiterating that it is "an ambition for the future".
Fukuoka, however, said as the Indian market "is more of a mature or saturated market", the priority for EKL is to ensure its products "get selected by the customer before the competition".
In order to achieve that, he said efforts are on to bring together the strengths of Escorts, which is cost competitive products and that of Kubota's technology and quality.
"Presently, we are thinking of putting Kubota quality in the low cost yet good tractor and putting it in the price sensitive market...If we end up putting the price higher because of the high quality, or make the price higher, then it will lose its value. So that is why, in this MTP, it is a very big theme on how to make good quality yet low-cost tractors," Fukuoka asserted.
He said as Kubota has been collaborating for the last five years now with Escorts, it has also learned "what are the points where we can improve the quality without increasing the price and that know-how will also be shared globally in order to contribute to Kubota's global growth".
In terms of network presence, Nanda said earlier Escorts was strong in North and West markets, while Kubota was strong in South and East. The coming together of the two entities has also helped in having a strong presence across India with over 1,500 plus dealers, Nanda said adding, "we still believe we have certain vacant spaces where we will be appointing dealers".
Fukuoka said recently top officials of Kubota's sales firm in the Americas, where the company has a strong sales network maintaining a high market share, came to India to share experience and advised EKL dealers "on what can be done" to increase market share.
On the export front, Fukuoka said,"By coming together as EKL now we are able to design tractors in India, procure things in India, and manufacture them in India and send them to the whole world through Kubota channels. This, of course, contributes to EKL's growth, but at the same time it also contributes to Kubota's growth." In Europe, he said Kubota has been able to recapture its market share in the compact tractor segment after introducing EKL's high quality and cost competitive product.
"This is something that is already a success story. We have been able to regain market share and similar things can be done in different markets. India made tractors can be sold through Kubota sales network, so that the sales company of Kubota can also get profit and EKL can also make profit," Fukuoka noted.
At present, exports account for 5 per cent of EKL's total sales and in the long term it is aiming to increase it to around 10-15 per cent.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
44 minutes ago
- Business Standard
Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai
The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations Press Trust of India Srinagar The Jammu and Kashmir Bank on Sunday announced the appointment of Ketan Kumar Joshi as its new chief financial officer for a term of three years. Joshi has replaced Fayaz Ahmad Ganai, a spokesperson of the J&K Bank said. The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations. "A seasoned professional in banking and finance, Joshi brings over two decades of extensive experience across Indian and international financial institutions," the spokesperson said. Before joining the J&K Bank, Joshi served as CFO at North East Small Finance Bank Ltd. (2019-2024), where he successfully led a number of critical initiatives. He also spearheaded the bank's system migration from FIS (PROFILE) to BSG (TURING), ensuring capital growth aligned with business expansion and regulatory requirements. Joshi has served in Afghanistan with Maiwand Bank, Bakhtar Bank, and Ghazanfar Bank. He also served as senior vice president at Bank of Tokyo-Mitsubishi UFJ Ltd, Mumbai. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Time of India
an hour ago
- Time of India
Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh
Beijing: Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. Live Events In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River , which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing USD 137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh.


Mint
an hour ago
- Mint
Torrent Pharma to acquire controlling stake in JB Chemicals from KKR
Ahmedabad-based drugmaker Torrent Pharmaceuticals is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR, at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities, the company announced on Sunday evening. The deal will strengthen Torrent's presence in the Indian market, as well as facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. Torrent will acquire a 46.39% equity stake (on a fully diluted basis) in JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share, followed by a mandatory open offer to acquire up to 26% of the company's shares from public shareholders, at an open offer price of ₹1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same share price as KKR, the company said in a release. The investment in JB Pharma yielded an over 5x return for KKR with a gross internal rate of return of about 36%, a person aware of the development, who did not wish to be quoted, told Mint. KKR has had a strong track record of healthcare investments in India, including a $600 million financing to Manipal Group recently and a 5x return on its investment in Max Healthcare in 2022. The acquisition will be followed by a merger between Torrent and JB Pharma through a scheme of arrangement. JB Pharma's shares rose 2.3% to ₹1,792.20 apiece, while those of Torrent Pharma settled 4.7% higher at ₹3,375 on the NSE on Friday. The acquisition will provide Torrent access to a fast-growing India franchise, with JB's leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology, strengthen Torrent's market share in the Indian market, and facilitate its entry into the CDMO segment. It will also aid consolidation in key international markets, the company said. 'Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint, offers immense potential to scale both revenue and profitability," Samir Mehta, executive chairman, Torrent Pharmaceuticals, said in the statement. 'Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent," he added. Torrent Pharma was engaged in prolonged talks to acquire KKR's stake in JB Pharma last year. The deal, however, fell through over valuation concerns. KKR acquired a 54% stake in JB Pharma from the promoters, the Mody family, in July 2020 for about ₹3,100 crore, or ₹745 per share. The investment firm sold over 5% of stake in the company in March 2025 through block deals for ₹1,459 crore, bringing its holding down to 47.84%. Torrent Pharmaceuticals has grown over the years through inorganic moves. In 2017, it acquired women's healthcare brands from Novartis, as well as Unichem's Indian branded business along with its Sikkim plant. In 2022, it acquired Curatio Healthcare for ₹2,000 crore. In an interview with the Economic Times earlier this month, Torrent's managing director-designate Aman Mehta said the company is aiming to be one of the top three pharma companies in the Indian market in the next three to five years. JB Pharma is one of the fastest growing pharma companies in India, and comes with flagship brands such as Cilacar, Metrogyl, Nicardia and Rantac. The company also exports its finished formulations to over 40 countries, including the US, and is a leading CDMO player in the segment of medicated lozenges. JB Pharma recorded revenue of ₹3,918 crore in FY24-25, growing 12% year-on-year. Of this, its revenue from the domestic market was ₹2,269 crore, growing 20% YoY. 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth as well as consistent improvement in profitability in the medium and long term," said Nikhil Chopra, chief executive officer and whole time director of JB Pharma.